001     144814
005     20240229123020.0
024 7 _ |a 10.1093/nutrit/nuz039
|2 doi
024 7 _ |a pmid:31504850
|2 pmid
024 7 _ |a 0029-6643
|2 ISSN
024 7 _ |a 1753-4887
|2 ISSN
024 7 _ |a altmetric:65577658
|2 altmetric
037 _ _ |a DKFZ-2019-02239
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Javelle, Florian
|b 0
245 _ _ |a Effects of 5-hydroxytryptophan on distinct types of depression: a systematic review and meta-analysis.
260 _ _ |a Lawrence, Kan.
|c 2020
|b Internat. Life Sciences Inst.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1601379704_14558
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2020 Jan 1;78(1):77-88#LA:C110#
520 _ _ |a Serotonergic dysfunction, including reduced central serotonin levels, is associated with different psychiatric syndromes, including depression. As a serotonin precursor, 5-hydroxytryptophan has long been used as a nonpharmacological treatment for depression.A systematic review and meta-analysis was conducted to determine the antidepressant effects of 5-hydroxytryptophan in depressed patients.MEDLINE (via PubMed) and Google Scholar were searched from inception to May 2018.Thirteen investigations were included in the systematic review (using PRISMA guidelines), and 7 in the full meta-analysis (pre-registered on PROSPERO: CRD42018104415).Analyses revealed a depression remission rate of 0.65 (95% confidence interval [CI], 0.55-0.78; remission rate [k] = 13), and this was confirmed by the questionnaire results, which revealed a large Hedges' g (1.11; 95%CI, 0.53-1.69). Methodological variability (in treatment duration, type of depression studied, experimental design, 5-hydroxytryptophan dosage) contributes to heterogeneity in the results (I2 = 76%, τ2 = 0.379). In addition, the OHAT (Office of Health Assessment and Translation risk of bias rating) tool suggested that, on the whole, current studies are relatively weak (few include placebo groups).Further trials should overcome these limitations by using placebo-controlled studies that include patients with well-defined depression diagnoses, along with strong characterization of psychological and physiological patient characteristics.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Lampit, Amit
|b 1
700 1 _ |a Bloch, Wilhelm
|b 2
700 1 _ |a Häussermann, Peter
|b 3
700 1 _ |a Johnson, Sheri L
|b 4
700 1 _ |a Zimmer, Philipp
|0 P:(DE-He78)d05b24af674d8ef2c455634434b67770
|b 5
|e Last author
|u dkfz
773 _ _ |a 10.1093/nutrit/nuz039
|g p. nuz039
|0 PERI:(DE-600)2066844-2
|n 1
|p 77-88
|t Nutrition reviews
|v 78
|y 2020
|x 1753-4887
909 C O |p VDB
|o oai:inrepo02.dkfz.de:144814
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)d05b24af674d8ef2c455634434b67770
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|2 G:(DE-HGF)POF3-300
|v Cancer risk factors and prevention
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2020
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NUTR REV : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1060
|2 StatID
|b Current Contents - Agriculture, Biology and Environmental Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b NUTR REV : 2017
920 2 _ |0 I:(DE-He78)C110-20160331
|k C110
|l Bewegung, Präventionsforschung und Krebs
|x 0
920 1 _ |0 I:(DE-He78)C110-20160331
|k C110
|l Bewegung, Präventionsforschung und Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C110-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21